Cite this answer
Vilon: quick citable summary
Vilon is listed by PeptaHub as a immune peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Vilon: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/vilon. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/vilon.
What is Vilon?
Vilon is a synthetic dipeptide (Lys-Glu) bioregulator from Khavinson's group. In a human monocytic cell line it suppresses LPS-induced TNF and IL-6; in mice it increased life span and slowed spontaneous tumor growth. No randomized human trials exist.
Overview
Vilon is a synthetic dipeptide (Lys-Glu, KE) bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a thymus-derived bioregulator that modulates immune function, particularly T-lymphocyte activity, and has been studied for its anti-aging and immunomodulatory properties in preclinical and Russian clinical research.
Mechanism of action
Vilon is proposed to act as an epigenetic regulator: Khavinson's group reports that short peptides of this class penetrate the nucleus and interact with double-stranded DNA in vitro, and molecular modeling has been used to predict sequence preferences. No sequence-specific binding site has been confirmed for Lys-Glu itself in a way that is tied to a functional outcome. In the human THP-1 monocytic cell line, Vilon suppressed TNF and IL-6 release stimulated by bacterial lipopolysaccharide and reduced monocyte adhesion to activated endothelium, alongside four other Khavinson peptides. In cultured lymphocytes from elderly donors, Vilon induced decondensation of facultative heterochromatin and reactivation of ribosomal genes. Vilon was originally derived from analysis of thymalin, a thymic polypeptide complex.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| immune modulation research | subcutaneous | 0.1–0.5 mg | daily for 10–20 days | Range quoted in supplier and Russian practice material. Not established by any published study, and no trial has tested this dose or the 10-day cycle against an outcome. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Vilon research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Vilon dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
The Vilon research base is almost entirely from Khavinson's group and its collaborators, in Russian-language journals or small in vitro reports. In mice, Vilon inhibited growth of spontaneous tumors and increased life span (Dokl Biol Sci 2000). In rats it altered digestive enzyme activity across age groups, and in a rat radiation model of premature aging it affected thymus and spleen structure. Human data is limited: a preliminary Russian series added Vilon to radical treatment of elderly stage III colorectal cancer patients and reported better 2-year survival and fewer complications, without randomization or a reported sample size in the abstract. In vitro, Vilon suppresses LPS-driven TNF and IL-6 in a human monocytic cell line. There are no randomized controlled trials of Vilon in any indication, and no Western replication of the animal longevity findings.[1][2][3][4][5][6]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Vilon for synergistic effects.
Legal status
Not FDA-approved. Developed and studied in Russia; sold as a research chemical in Western markets. Not approved for human therapeutic use outside Russia. Classified as a research peptide in the US and EU.
Sourcing & access
Research compound
Vilon is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Vilon is a synthetic dipeptide (Lys-Glu, KE) developed by Professor Vladimir Khavinson as a thymus-derived bioregulator. It modulates T-lymphocyte activity and has been studied for anti-aging and immunomodulatory properties in preclinical and Russian clinical research.
The proposed mechanism is epigenetic: short peptides of this class are reported to enter the nucleus and interact with DNA, though no confirmed sequence-specific site has been tied to a functional effect for Lys-Glu. Measured effects are in vitro. In a human monocytic (THP-1) cell line Vilon suppressed LPS-stimulated TNF and IL-6 release, and in cultured lymphocytes from elderly donors it decondensed facultative heterochromatin.
Reported side effects are limited to mild injection site redness and transient fatigue. The long-term safety profile is unknown. No large randomized controlled trials meeting Western standards have been conducted. It is not FDA-approved.
No human dose has been established in a published study. The 0.1 to 0.5 mg subcutaneous ranges and 10-day cycles quoted for Vilon come from supplier and practice material rather than a trial that tested them against an outcome, and oral bioavailability has not been characterized.
Research references
- A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of micePubMed
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old peoplePubMed
- Effect of the dipeptide vilon on activity of digestive enzyme in rats of various agesPubMed
- [The effect of vilon on the thymus and spleen in a radiation model of premature aging] (Russian-language)PubMed
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell LinePubMed
- [Application of peptide bioregulator in complex treatment of elderly cancer patients] (Russian-language)PubMed